Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies.
Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies. Blood Adv. 2023 02 28; 7(4):549-554.
PMID: 36001442
Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature.
Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature. Leuk Lymphoma. 2021 07; 62(7):1765-1769.
PMID: 33559517
Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses.
Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses. Leuk Lymphoma. 2021 06; 62(6):1497-1501.
PMID: 33535838
Navigating Dilemmas in Treatment Choice: Our Approach to Supplemental Apheresis Prior to Enrollment in Early- Phase Cellular Therapy Clinical Trials.
Navigating Dilemmas in Treatment Choice: Our Approach to Supplemental Apheresis Prior to Enrollment in Early- Phase Cellular Therapy Clinical Trials. Transplant Cell Ther. 2021 02; 27(2):105-107.
PMID: 33781544
Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients.
Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients. J Geriatr Oncol. 2021 05; 12(4):585-591.
PMID: 33162369
Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic.
Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic. Biol Blood Marrow Transplant. 2020 07; 26(7):1239-1246.
PMID: 32298807
Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell Transplantation.
Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020 05; 26(5):1025-1027.
PMID: 32018063
Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas.
Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas. Ther Adv Hematol. 2020; 11:2040620720902899.
PMID: 32064069
Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival.
Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival. Bone Marrow Transplant. 2020 06; 55(6):1161-1168.
PMID: 31992847
Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study.
Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study. J Immunother Cancer. 2020 01; 8(1).
PMID: 31940591